CDKN2A and sarcoma: Of the 74 p16/p19−/−xN-tva mice injected, 22 (30%) developed soft tissue sarcoma at, or around, the injection site with a median onset of 23 weeks (range 8–36 weeks) (Table 1 and Figure 2).